The Indonesian Health Ministry announced that a study involving healthcare workers who received Sinovac Biotech's CoronaVac vaccine proved that it is 98 percent effective at preventing death and 96 percent effective at preventing hospitalization.

Lead researcher and health official Pandji Dhewantara said the study was based on data collected from healthcare workers in Jakarta who got vaccinated between January and March.

The Sinovac vaccine has been so far authorized in 32 countries and jurisdictions, according to the WHO’s Strategic Advisory Group of Experts (SAGE).

According to Al Jazeera, SAGE reviewed Sinovac’s CoronaVac during phase three of clinical trials in China, Brazil, Indonesia, Turkey and Chile. SAGE announced that “We are very confident that two doses of CoronaVac are efficacious in preventing PCR-confirmed COVID-19 in adults (18-59 years).”

This came after it had previously expressed “very low confidence” in the data provided by Chinese company Sinopharm regarding the risk of serious side-effects in some patients who received their COVID-19 vaccine.

However, they were overall confident in its ability to prevent the disease, according to Reuters.